Sentiment-Signal
25,5
Bearisch
Composite Score (0–100)
Insider (25%)
47.1
1 Insider, 5,0M $ Volumen
Institutionell (22,5%)
25.7
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 12.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 12.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ssly stated by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Dire |
| 05.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | , or that are associated with, the reduction. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 07.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | y stated by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 04.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 06.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 02.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
Stammdaten
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | ALX ONCOLOGY HOLDINGS INC |
|---|---|
| Ticker | ALXO |
| CIK | 0001810182 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 00166b105 |
|---|---|
| ISIN | US00166B1052 |
| Typ | Common Stock |
| Marktkapitalisierung | 85,1 Mio. USD |
| Beta | 0,50 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -101,695,000 | -1.90 | 59,046,000 | 25,981,000 | |
| 2025-09-30 | 10-Q | -22,144,000 | -0.41 | 82,723,000 | 44,800,000 | |
| 2025-06-30 | 10-Q | -25,949,000 | -0.49 | 95,320,000 | 64,415,000 | |
| 2025-03-31 | 10-Q | -30,754,000 | -0.58 | 120,900,000 | 88,295,000 | |
| 2024-12-31 | 10-K | -134,850,000 | -2.58 | 147,775,000 | 113,618,000 | |
| 2024-09-30 | 10-Q | -30,707,000 | -0.58 | 185,715,000 | 136,807,000 | |
| 2024-06-30 | 10-Q | -39,399,000 | -0.76 | 214,618,000 | 159,317,000 | |
| 2024-03-31 | 10-Q | -35,581,000 | -0.71 | 212,650,000 | 164,195,000 | |
| 2023-12-31 | 10-K | -160,805,000 | -3.74 | 242,553,000 | 189,712,000 | |
| 2023-09-30 | 10-Q | -50,990,000 | -1.24 | 220,107,000 | 168,752,000 | |
| 2023-06-30 | 10-Q | -34,159,000 | -0.84 | 245,932,000 | 212,692,000 | |
| 2023-03-31 | 10-Q | -30,184,000 | -0.74 | 278,138,000 | 240,388,000 | |
| 2022-12-31 | 10-K | 0 | -123,482,000 | -3.03 | 306,489,000 | 263,464,000 |
| 2022-09-30 | 10-Q | -35,320,000 | -0.87 | 317,689,000 | 286,963,000 | |
| 2022-06-30 | 10-Q | -32,920,000 | -0.81 | 346,018,000 | 316,319,000 | |
| 2022-03-31 | 10-Q | -24,533,000 | -0.60 | 363,676,000 | 343,596,000 | |
| 2021-12-31 | 10-K | 0 | -83,463,000 | -2.07 | 380,183,000 | 363,049,000 |
| 2021-09-30 | 10-Q | -24,566,000 | -0.61 | 399,728,000 | 385,172,000 | |
| 2021-06-30 | 10-Q | -16,274,000 | -0.40 | 421,289,000 | 405,014,000 | |
| 2021-03-31 | 10-Q | -14,185,000 | 432,910,000 | 418,484,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 3,304,619 | 0 | 3,304,619 | 3,734,219 | Neu | +100,0% | |
| Redmile Group, LLC | 3,264,718 | 0 | 3,264,718 | 3,689,131 | Neu | +100,0% | |
| Almitas Capital LLC | 2,536,891 | 0 | 2,536,891 | 2,866,687 | Neu | +100,0% | |
| VANGUARD GROUP INC | 1,630,940 | 0 | 1,630,940 | 1,842,962 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,422,882 | 0 | 1,422,882 | 1,607,857 | Neu | +100,0% | |
| UBS Group AG | 865,991 | 0 | 865,991 | 978,570 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 640,205 | 0 | 640,205 | 723,432 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 531,845 | 0 | 531,845 | 600,985 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 474,781 | 0 | 474,781 | 536,503 | Neu | +100,0% | |
| BlackRock, Inc. | 450,430 | 0 | 450,430 | 508,986 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 423,099 | 0 | 423,099 | 478,102 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 353,696 | 0 | 353,696 | 399,827 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 206,461 | 0 | 206,461 | 233,300 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 184,327 | 0 | 184,327 | 208,290 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 170,432 | 0 | 170,432 | 192,588 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 149,097 | 0 | 149,097 | 168,480 | Neu | +100,0% | |
| STATE STREET CORP | 124,228 | 0 | 124,228 | 140,378 | Neu | +100,0% | |
| BANK OF NOVA SCOTIA | 105,858 | 0 | 105,858 | 119,620 | Neu | +100,0% | |
| IEQ CAPITAL, LLC | 92,233 | 0 | 92,233 | 104,223 | Neu | +100,0% | |
| MORGAN STANLEY | 83,757 | 0 | 83,757 | 94,646 | Neu | +100,0% | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 76,072 | 0 | 76,072 | 85,961 | Neu | +100,0% | |
| Callan Family Office, LLC | 28,308 | 0 | 28,308 | 31,988 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 26,376 | 0 | 26,376 | 29,805 | Neu | +100,0% | |
| HC Advisors, LLC | 23,900 | 0 | 23,900 | 27,007 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 22,718 | 0 | 22,718 | 25,671 | Neu | +100,0% | |
| JSF Financial, LLC | 17,500 | 0 | 17,500 | 19,775 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 17,262 | 0 | 17,262 | 19,506 | Neu | +100,0% | |
| NINE MASTS CAPITAL Ltd | 15,475 | 0 | 15,475 | 17,487 | Neu | +100,0% | |
| MONETA GROUP INVESTMENT ADVISORS LLC | 15,196 | 0 | 15,196 | 17,171 | Neu | +100,0% | |
| COMMONWEALTH EQUITY SERVICES, LLC | 15,102 | 0 | 15,102 | 17,070 | Neu | +100,0% | |
| FMR LLC | 12,986 | 0 | 12,986 | 14,674 | Neu | +100,0% | |
| Abel Hall, LLC | 12,598 | 0 | 12,598 | 14,236 | Neu | +100,0% | |
| SIMPLEX TRADING, LLC | 11,753 | 0 | 11,753 | 13,279 | Neu | +100,0% | |
| BARCLAYS PLC | 10,515 | 0 | 10,515 | 11,882 | Neu | +100,0% | |
| HSBC HOLDINGS PLC | 10,105 | 0 | 10,105 | 11,621 | Neu | +100,0% | |
| Tower Research Capital LLC (TRC) | 3,142 | 0 | 3,142 | 3,550 | Neu | +100,0% | |
| ACADIAN ASSET MANAGEMENT LLC | 1,374,273 | 0 | 1,374,273 | 1,552 | Neu | +100,0% | |
| NISA INVESTMENT ADVISORS, LLC | 1,106 | 0 | 1,106 | 1,250 | Neu | +100,0% | |
| Bradley & Co. Private Wealth Management, LLC | 1,000 | 0 | 1,000 | 1,130 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 963 | 0 | 963 | 1,000 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 480 | 0 | 480 | 542 | Neu | +100,0% | |
| DekaBank Deutsche Girozentrale | 41,000 | 0 | 41,000 | 508 | Neu | +100,0% | |
| SBI Securities Co., Ltd. | 412 | 0 | 412 | 466 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 99 | 0 | 99 | 112 | Neu | +100,0% | |
| GSA CAPITAL PARTNERS LLP | 92,654 | 0 | 92,654 | 105 | Neu | +100,0% | |
| Optiver Holding B.V. | 27 | 0 | 27 | 31 | Neu | +100,0% | |
| Virtu Financial LLC | 13,702 | 0 | 13,702 | 15 | Neu | +100,0% | |
| CWM, LLC | 96 | 0 | 96 | 0 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Pinto Shelly | Officer, SVP, FINANCE AND CAO | Open Market Sale | -565 | 2.27 | -1,282.55 | -0,2% | |
| 2026-02-02 | GOODMAN COREY S | Director, 10% Owner | Open Market Purchase | 3,184,713 | 1.57 | 4,999,999.41 | +967,7% | |
| 2026-01-06 | Pinto Shelly | Officer, SVP, FINANCE AND CAO | Open Market Sale | -3,925 | 1.11 | -4,356.75 | -0,8% | |
| 2025-09-17 | Lettmann Jason | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Purchase | 71,163 | 1.08 | 76,891.62 | +14,9% | |
| 2025-09-16 | Lettmann Jason | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Purchase | 21,070 | 1.07 | 22,460.62 | +4,3% | |
| 2025-08-18 | Shantharam Harish | Officer, Chief Financial Officer | Open Market Purchase | 75,000 | 0.78 | 58,402.50 | +11,3% | |
| 2025-08-15 | Lettmann Jason | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2,382 | 0.64 | -1,525.43 | -0,3% | |
| 2025-08-15 | Pinto Shelly | Officer, SVP, FINANCE AND CAO | Open Market Sale | -611 | 0.64 | -391.28 | -0,1% | |
| 2025-07-07 | Pinto Shelly | Officer, SVP, FINANCE AND CAO | Open Market Sale | -2,011 | 0.45 | -905.15 | -0,2% | |
| 2025-06-30 | Pinto Shelly | Officer, SVP, FINANCE AND CAO | Open Market Sale | -1,532 | 0.43 | -658.76 | -0,1% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 3,304,619 | 3,734,219 | 19.06 |
| Redmile Group, LLC | 3,264,718 | 3,689,131 | 18.83 |
| Almitas Capital LLC | 2,536,891 | 2,866,687 | 14.63 |
| VANGUARD GROUP INC | 1,630,940 | 1,842,962 | 9.40 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,422,882 | 1,607,857 | 8.20 |
| UBS Group AG | 865,991 | 978,570 | 4.99 |
| TWO SIGMA INVESTMENTS, LP | 640,205 | 723,432 | 3.69 |
| BANK OF AMERICA CORP /DE/ | 531,845 | 600,985 | 3.07 |
| BANK OF MONTREAL /CAN/ | 474,781 | 536,503 | 2.74 |
| BlackRock, Inc. | 450,430 | 508,986 | 2.60 |
| RENAISSANCE TECHNOLOGIES LLC | 423,099 | 478,102 | 2.44 |
| GEODE CAPITAL MANAGEMENT, LLC | 353,696 | 399,827 | 2.04 |
| JANE STREET GROUP, LLC | 206,461 | 233,300 | 1.19 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 184,327 | 208,290 | 1.06 |
| CITADEL ADVISORS LLC | 170,432 | 192,588 | 0.98 |
| NORTHERN TRUST CORP | 149,097 | 168,480 | 0.86 |
| STATE STREET CORP | 124,228 | 140,378 | 0.72 |
| BANK OF NOVA SCOTIA | 105,858 | 119,620 | 0.61 |
| IEQ CAPITAL, LLC | 92,233 | 104,223 | 0.53 |
| MORGAN STANLEY | 83,757 | 94,646 | 0.48 |